BBNX — Beta Bionics Balance Sheet
0.000.00%
- $475.10m
- $692.90m
- $65.12m
Annual balance sheet for Beta Bionics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Cash and Equivalents | |||
Short Term Investments | |||
Cash and Short Term Investments | 27.7 | 96.7 | 104 |
Net Total Accounts Receivable | |||
Net Total Receivables | 0 | 4.45 | 12 |
Total Inventory | |||
Prepaid Expenses | |||
Total Other Current Assets | |||
Total Current Assets | 28.5 | 104 | 133 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 6.87 | 6.2 | 11.4 |
Other Long Term Assets | |||
Total Assets | 35.5 | 110 | 150 |
Accounts Payable | |||
Accrued Expenses | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 8.87 | 10.6 | 21.1 |
Total Long Term Debt | |||
Total Debt | |||
Total Other Liabilities | |||
Total Liabilities | 22.5 | 51.4 | 73.6 |
Non Redeemable Preferred Stock | |||
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Unrealized Gain / Loss | |||
Total Equity | 13 | 58.6 | 76 |
Total Liabilities & Shareholders' Equity | 35.5 | 110 | 150 |
Total Common Shares Outstanding |